stockrow
Friday 6 November 2026
Export SUPN’s income statement to Excel — free account
Indivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
26.00
0.74
−2.77%
Follow SUPN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 4 | 5 | 4 |
+8 more TTM periods Free account |
| (337.83%) | (153.12%) | (117.21%) | (96.33%) | ||
| 32.82% | 26.52% | 19.60% | 16.69% | ||
ROIC |
283.03% | 460.53% | 124.25% | 629.81% | |
Return on Tangible Assets |
(138.34%) | 1,873.68% | 560.00% | (177.97%) | |
Average Days of Receivables |
76.03 | 78.70 | 80.64 | 75.12 | |
Free Cash Flow per Share |
0.26 | (0.93) | (1.55) | (0.76) | |
Free Cash Flow |
31.00 | (111.00) | (192.00) | (95.00) | |
Capital Expenditures |
(65.00) | (71.00) | (81.00) | (68.00) | |
| Other line items | |||||
Cash ROIC |
4.23% | (22.16%) | (37.14%) | (22.84%) | |
Accounts Receivable Turnover |
4.92 | 5.02 | 4.63 | 4.57 | |
Accounts Payable Turnover |
1.05 | 1.19 | 1.34 | 1.06 | |
Inventory Turnover |
1.37 | 1.61 | 1.54 | 1.54 | |
Average Days of Payables |
317.62 | 313.29 | 268.47 | 370.94 | |
Days of Inventory on Hand |
261.47 | 228.13 | 229.26 | 227.01 | |
Tax Rate |
(0.16) | (0.10) | (0.15) | (0.12) | |
Research and Development Expense of Revenue |
3.93% | 6.16% | 7.05% | 7.83% | |
Selling, General and Administrative Expense of Revenue |
40.35% | 44.25% | 48.45% | 51.17% | |
Share Based Compensation of Revenue |
2.40% | 2.40% | 2.25% | 2.10% | |
Interest Coverage |
32.76 | 15.56 | 8.30 | 5.82 | |
Operating CF/Net income |
0.21 | (0.11) | (0.44) | (0.13) | |
Depreciation/Fixed assets |
0.08 | 0.10 | 0.12 | 0.14 | |
Capex/Depreciation |
(4.64) | (4.18) | (4.26) | (3.40) | |
Revenue per Share |
11.64 | 11.18 | 10.40 | 9.91 | |
Operating CF per Share |
0.81 | (0.34) | (0.90) | (0.22) | |
Capex per Share |
(0.55) | (0.60) | (0.65) | (0.54) | |
Capex to Sales |
0.05 | 0.05 | 0.06 | 0.05 |
Columns are period end dates · fundamentals updated 2 Nov 2026